



Bristol-Myers Squibb Canada

2344 Alfred Nobel, Suite 300, Saint-Laurent (Québec) H4S 0A4
Tel: (514) 333-3200 Fax: (514) 334-3620

June 29th, 2018

Dear Healthcare Professional,

Bristol-Myers Squibb would like to inform you that the sale and distribution of VIDEX[®] EC (didanosine enteric coated beadlets capsules, 125, 200, 250 and 400 mg) and ZERIT[®] (stavudine capsules 15, 20, 30 and 40mg) will be globally discontinued.

The Global discontinuation of VIDEX EC and ZERIT is voluntary and is not the result of any quality, safety or efficacy issues regarding the products.

VIDEX EC, in combination with other antiretroviral agents, is indicated for the treatment of HIV-1 infection in adults.

ZERIT, in combination with other antiretroviral agents, is indicated for the treatment of HIV-1 infection.

Bristol-Myers Squibb has carefully evaluated the potential impact of discontinuing VIDEX EC and ZERIT, which have been available since 2002 and 1996 respectively, and concluded there would be limited clinical impact given the availability of numerous newer medications for HIV.

Therefore, no later than March 31st 2020, Bristol-Myers Squibb will cease the distribution of VIDEX EC and ZERIT in Canada.

If you have questions or require additional information regarding the discontinuation of VIDEX EC or ZERIT, please contact Bristol-Myers Squibb Canada at 1-800-267-0005 or via e-mail at otc.canada@bms.com.

For medical information requests, please contact our Medical Information Services at 1-866-463-6267 or at medical.canada@bms.com.

Best Regards,

Babak Abbaszadeh, M.D, M.B.A.
Country Medical Director
Bristol-Myers Squibb Canada